BiotechTube

Enzalutamide + Enzalutamide with Sorafenib

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

Dec 1, 2015 → Mar 1, 2021

NCT ID
NCT02642913

About Enzalutamide + Enzalutamide with Sorafenib

Enzalutamide + Enzalutamide with Sorafenib is a phase 1 stage product being developed by Astellas Pharma for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02642913. Target conditions include Hepatocellular Carcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Hepatocellular Carcinoma were approved

Approved (5) Terminated (2) Active (14)
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty OintmentBayerApproved
✅Xenetix-CT perfusion imagingGuerbetApproved
✅Gadoterate meglumineGuerbetApproved
🔄Ramucirumab + PlaceboEli LillyPhase 3
🔄Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02642913Phase 1Completed

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
Ramucirumab + PlaceboEli LillyPhase 3
40
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
44
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
29
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
35
Tivantinib + PlaceboDaiichi SankyoPhase 3
40
OSI-906 + PlaceboAstellas PharmaPhase 2
27
Enzalutamide + PlaceboAstellas PharmaPhase 2
35
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
25
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
42
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
42
camrelizumab& apatinibSun PharmaceuticalPhase 2
31
LenvatinibEisaiPre-clinical
26
Lenvatinib PillEisaiPhase 2
39
Sorafenib + SorafenibEisaiPhase 1/2
32
LenvatinibEisaiPhase 2
42
Lenvatinib + NivolumabEisaiPhase 2
35
H3B-6527EisaiPhase 1
29